• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-L1 表达由 22C3 抗体评估，比 SP142/SP263 抗体在乳腺癌患者切除术后更能作为预后标志物。

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.

机构信息

Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Institute for Breast Cancer Precision Medicine, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Sci Rep. 2021 Oct 1;11(1):19555. doi: 10.1038/s41598-021-97250-2.

DOI:10.1038/s41598-021-97250-2
PMID:34599199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8486819/
Abstract

Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) analysis. We retrospectively investigated tumor tissues derived from 316 breast cancer cases, by constructing tissue microarrays and by performing IHC staining. The immune-cell expression rate (for SP142 and SP263) and combined proportional score (for 22C3) were evaluated, and survival outcomes were analyzed. Prediction models were developed, and values of Harrel's c-index and areas under curves were calculated to compare the discriminatory power. Negative PD-L1 expression based on the 22C3-IHC assay was determined to be an independent prognostic marker for recurrence-free survival (RFS, P = 0.0337) and distant metastasis-free survival (DMFS, P = 0.0131). However, PD-L1 expression based on SP142- and SP263-IHC assays did not reveal a prognostic impact. Among the three antibodies, adding PD-L1 expression data obtained via 22C3-IHC assay to the null model led to a significant improvement in the discriminatory power of RFS and DMFS. We suggest that PD-L1 expression based on the 22C3-IHC assay is a superior prognostic marker than that based on SP142- and SP263-IHC assays.

摘要

免疫检查点抑制剂 (ICI) 在治疗实体瘤方面已显示出疗效。然而，目前尚无用于 ICI 的统一预测生物标志物。我们旨在比较使用三种 PD-L1 抗体 (SP142、SP263 和 22C3) 进行免疫组织化学 (IHC) 分析的预后影响。我们通过构建组织微阵列并进行 IHC 染色，对 316 例乳腺癌病例的肿瘤组织进行了回顾性研究。评估了 SP142 和 SP263 的免疫细胞表达率和联合比例评分 (22C3)，并分析了生存结果。建立了预测模型，并计算了 Harrell's c 指数和曲线下面积值，以比较判别能力。基于 22C3-IHC 检测的阴性 PD-L1 表达被确定为无复发生存率 (RFS，P=0.0337) 和远处无转移生存率 (DMFS，P=0.0131) 的独立预后标志物。然而，基于 SP142 和 SP263-IHC 检测的 PD-L1 表达并未显示出预后影响。在这三种抗体中，将通过 22C3-IHC 检测获得的 PD-L1 表达数据添加到零模型中，可显著提高 RFS 和 DMFS 的判别能力。我们认为，基于 22C3-IHC 检测的 PD-L1 表达比基于 SP142 和 SP263-IHC 检测的 PD-L1 表达更能预测预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/350a67fd60e0/41598_2021_97250_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/894827b81686/41598_2021_97250_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/df227a42de73/41598_2021_97250_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/022fbc7501d1/41598_2021_97250_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/590137a540ec/41598_2021_97250_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/350a67fd60e0/41598_2021_97250_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/894827b81686/41598_2021_97250_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/df227a42de73/41598_2021_97250_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/022fbc7501d1/41598_2021_97250_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/590137a540ec/41598_2021_97250_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9490/8486819/350a67fd60e0/41598_2021_97250_Fig5_HTML.jpg

相似文献

1
PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.PD-L1 表达由 22C3 抗体评估，比 SP142/SP263 抗体在乳腺癌患者切除术后更能作为预后标志物。
Sci Rep. 2021 Oct 1;11(1):19555. doi: 10.1038/s41598-021-97250-2.
2
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.在基于人群的三阴性乳腺癌患者队列中，比较 SP142 和 22C3 PD-L1 检测试剂盒在其临床建立的评分算法中的应用。
Breast Cancer Res. 2023 Oct 10;25(1):123. doi: 10.1186/s13058-023-01724-2.
3
PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.使用SP263、SP142和22C3抗体检测膀胱尿路上皮癌中PD-L1的免疫组化表达：一项比较研究。
Ann Diagn Pathol. 2024 Apr;69:152267. doi: 10.1016/j.anndiagpath.2024.152267. Epub 2024 Jan 20.
4
[Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].三阴性乳腺癌中PD-L1（22C3）和PD-L1（SP142）的表达比较及临床意义
Zhonghua Zhong Liu Za Zhi. 2022 Mar 23;44(3):260-267. doi: 10.3760/cma.j.cn112152-20200803-00704.
5
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌中 PD-L1 免疫组织化学检测方法的比较。
J Natl Cancer Inst. 2021 Nov 29;113(12):1733-1743. doi: 10.1093/jnci/djab108.
6
SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.SP142 PD-L1 评分在三阴性乳腺癌中显示出较高的观察者间和观察者内一致性，但与其他 PD-L1 克隆 SP263 和 22C3 的总一致性百分比较低。
Am J Surg Pathol. 2021 Aug 1;45(8):1108-1117. doi: 10.1097/PAS.0000000000001701.
7
Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.绘制用于免疫肿瘤治疗的程序性细胞死亡配体-1 预测性免疫组织化学检测中使用的抗体结合位点图谱。
Mod Pathol. 2020 Apr;33(4):518-530. doi: 10.1038/s41379-019-0372-z. Epub 2019 Sep 26.
8
Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.PD-L1 检测分析方法的比较及其在弥漫性大 B 细胞淋巴瘤评估中的意义。
Cancer Med. 2019 Jul;8(8):3831-3845. doi: 10.1002/cam4.2316. Epub 2019 May 31.
9
Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.关于非小细胞肺癌中PD-L1表达的22C3和SP142免疫组织化学检测方法一致性的评估
Sci Rep. 2017 Dec 5;7(1):16956. doi: 10.1038/s41598-017-17034-5.
10
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.程序性死亡配体 1 免疫组织化学检测：非小细胞肺癌中分析检测方法及临床应用的综述。
J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20.

引用本文的文献

1
Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.人类表皮生长因子受体-2 表达及卵巢癌患者的后续动态变化。
Sci Rep. 2024 Apr 5;14(1):7992. doi: 10.1038/s41598-024-57515-y.
2
Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.尿液中 Alix 归一化的外泌体程序性死亡配体 1 分析可实现对尿路上皮癌的精准监测。
Cancer Sci. 2024 May;115(5):1602-1610. doi: 10.1111/cas.16106. Epub 2024 Mar 13.
3
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.

本文引用的文献

1
Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.三阴性乳腺癌中SP142与22C3/SP263检测法检测程序性死亡配体1表达的一致性
J Breast Cancer. 2020 Jun;23(3):303-313. doi: 10.4048/jbc.2020.23.e37.
2
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.阿特珠单抗联合或不联合化疗治疗转移性尿路上皮癌（IMvigor130）：一项多中心、随机、安慰剂对照的 3 期临床试验。
Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0.
3
Pembrolizumab for Early Triple-Negative Breast Cancer.
在基于人群的三阴性乳腺癌患者队列中，比较 SP142 和 22C3 PD-L1 检测试剂盒在其临床建立的评分算法中的应用。
Breast Cancer Res. 2023 Oct 10;25(1):123. doi: 10.1186/s13058-023-01724-2.
4
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience.基于下一代测序和免疫组织化学的精准医学在卵巢癌中的应用：真实世界经验。
J Gynecol Oncol. 2023 Nov;34(6):e70. doi: 10.3802/jgo.2023.34.e70. Epub 2023 Jun 26.
5
Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer.复发性或晚期宫颈癌患者的综合基因组和免疫组化特征以及免疫治疗结果
Front Oncol. 2023 May 15;13:1156973. doi: 10.3389/fonc.2023.1156973. eCollection 2023.
6
PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy.新辅助化疗后不完全病理缓解的乳腺浸润性导管癌中 PD-L1 的表达。
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221078433. doi: 10.1177/03946320221078433.
帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
4
High A20 expression negatively impacts survival in patients with breast cancer.高表达的 A20 对乳腺癌患者的生存产生负面影响。
PLoS One. 2019 Aug 26;14(8):e0221721. doi: 10.1371/journal.pone.0221721. eCollection 2019.
5
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
6
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.一项随机 II 期研究，旨在探讨在早期三阴性乳腺癌中，在蒽环类药物紫杉烷为基础的新辅助治疗中加入度伐利尤单抗的效果：GeparNuevo 研究的临床结果和生物标志物分析。
Ann Oncol. 2019 Aug 1;30(8):1279-1288. doi: 10.1093/annonc/mdz158.
7
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.随机 III 期 KEYNOTE-045 试验：帕博利珠单抗对比紫杉醇、多西他赛或长春氟宁在复发性晚期尿路上皮癌中的应用：超过 2 年随访结果。
Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.
8
Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.与手术标本相比，使用小组织样本进行PD-L1检测的可靠性。
Medicine (Baltimore). 2019 Apr;98(14):e14972. doi: 10.1097/MD.0000000000014972.
9
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.PD-L1 在乳腺癌中的表达：亚型表达与预后意义：系统评价。
Breast Cancer Res Treat. 2019 Apr;174(3):571-584. doi: 10.1007/s10549-019-05130-1. Epub 2019 Jan 10.
10
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.